TABLE 2.
Characteristics of 40 mRCC patients according to ICI response groups
| Characteristic | OR (n = 12) | SD (n = 13) | PD (n = 15) | P value |
|---|---|---|---|---|
| Median age at ICI Treatment (IQR) | 68.0 (58.5‐72.8) | 73.0 (63.0‐79.0) | 65.0 (58.5‐75.0) | .660 |
| Gender, n (%) | ||||
| Female (n = 9) | 2 (16.7) | 3 (23.1) | 4 (26.7) | .895 |
| Male (n = 31) | 10 (83.3) | 10 (76.9) | 11 (73.3) | |
| ICI Treatment | ||||
| Nivolumab only (n = 32) | 8 (66.7) | 12 (92.3) | 12 (80.0) | .321 |
| Nivolumab and ipilimumab (n = 6) | 2 (16.7) | 1 (7.7) | 3 (20.0) | |
| Tyrosine kinase inhibitors and PD (L)‐1 Ab (n = 2) | 2 (16.7) | 0 (0.0) | 0 (0.0) | |
| Median ICI lines | 2.0 (1.0‐3.0) | 3.0 (2.0‐3.0) | 3.0 (2.0‐3.5) | .622 |
|
Median number of metastatic organs (IQR) |
2.0 (1.5‐3.0) | 2.0 (1.0‐2.0) | 2.0 (1.0‐2.0) | .399 |
| Pathological type | ||||
| CCRCC (n = 36) | 11 (91.7) | 11 (84.6) | 14 (93.3) | .821 |
| Others (n = 4) | 1 (8.3) | 2 (15.4) | 1 (6.7) | |
| Furman grading of RCC, n (%) | ||||
| Grade 1‐2 (n = 32) | 7 | 12 | 13 | .189 |
| Grade 3‐4 (n = 7) | 4 | 1 | 2 | |
| Not applicable (n = 1) | 1 | 0 | 0 | |
| Pathological T stage, n (%) | ||||
| pT1 (n = 13) | 3 (25.0) | 5 (38.5) | 5 (33.3) | .841 |
| pT2 (n = 8) | 2 (16.7) | 4 (30.8) | 2 (13.3) | |
| pT3 (n = 17) | 6 (50.0) | 4 (30.8) | 7 (46.7) | |
| pT4 (n = 2) | 1 (8.3) | 0 (0.0) | 1 (6.7) | |
| International Metastatic RCC Database Consortium risk classification | ||||
| Favorable (n = 8) | 3 (25.0) | 2 (15.4) | 3 (20.0) | .980 |
| Intermediate (n = 28) | 8 (66.7) | 10 (76.9) | 10 (66.7) | |
| Poor (n = 4) | 1 (8.3) | 1 (7.7) | 2 (13.3) | |
| Kyn levels, n (%) | ||||
| 1‐2 (n = 25) | 11 (91.7) | 8 (61.5) | 6 (40.0) | .026 |
| 3‐4 (n = 15) | 1 (8.3) | 5 (38.5) | 9 (60.0) | |
| TDO levels, n (%) | ||||
| 1‐2 (n = 25) | 10 (83.3) | 11 (84.6) | 4 (26.7) | .002 |
| 3‐4 (n = 15) | 2 (16.7) | 2 (15.4) | 11 (73.3) | |
| IDO1 levels, n (%) | ||||
| 1‐2 (n = 26) | 8 (66.7) | 7 (53.8) | 9 (60.0) | .919 |
| 3‐4 (n = 14) | 4 (33.3) | 6 (46.2) | 6 (40.0) | |
| PD‐L1 levels, n (%) | ||||
| CPS 1‐2 (n = 16) | 5 (41.7) | 5 (38.5) | 6 (40.0) | 1.000 |
| CPS 3‐4 (n = 24) | 7 (58.3) | 8 (61.5) | 9 (60.0) | |
| Median FOXP3 (IQR) | 3.5 (2‐8) | 5.0 (4.0‐6.0) | 7.0 (4.0‐8.0) | .042 |
Abbreviations: CCRCC, clear cell RCC; CPS, combined positive score; FOXP3, forkhead box P3; ICI, immune checkpoint inhibitor; IDO1, indoleamine 2,3‐dioxygenase 1; IQR, interquartile range; mRCC, metastatic RCC; OR, objective response; PD, progressive disease; PD‐L1, programmed cell death–ligand 1; RCC, renal cell carcinoma; stable disease (SD); TDO, tryptophan 2,3‐dioxygenase.